logo

Dicerna Pharmaceuticals, Inc. (DRNA)



Trade DRNA now with
  Date
  Headline
2/10/2020 7:33:20 AM Dicerna Appoints Stephen Doberstein To Board
1/2/2020 7:35:48 AM Dicerna Reports Closing Of Deal With Novo Nordisk For Development Of RNAi For Liver-Related Cardio-Metabolic Diseases
12/19/2019 7:33:43 AM Dicerna(tm) Announces Closing Of Worldwide Collaboration And Licensing Agreement With Roche
12/17/2019 7:35:31 AM Dicerna Gets Orphan Drug Designation From EC For DCR-A1AT For Congenital Alpha-1 Antitrypsin Deficiency
11/18/2019 6:02:31 AM Dicerna, Novo Nordisk To Discover, Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
9/19/2019 4:07:20 PM Dicerna Appoints Patrick Gray To Board Of Directors
7/15/2019 7:36:54 AM Dicerna Receives Breakthrough Therapy Designation For DCR-PHXC For Treatment Of Primary Hyperoxaluria Type 1
6/20/2019 7:34:31 AM Dicerna Pharma Appoints Bernd Hoppe As VP, Global Medical Affairs, Effective July 1
3/29/2019 6:36:26 AM Dicerna Announces Presentation Of Updated Data Demonstrating Utility Of DCR-PHXC In Treating PH1 And PH2
1/28/2019 7:37:07 AM Dicerna Announces Dosing Of First Volunteer In Phase 1 Clinical Trial Of DCR-HBVS Designed For Chronic Hepatitis B Virus
12/19/2018 7:30:45 AM Dicerna Announces Closing Of Global Licensing And Research Collaboration With Eli Lilly
10/29/2018 6:00:51 AM Lilly And Dicerna Announce RNAi Licensing And Research Collaboration
  
 
>